← back to search

Eva Baecklund

Science for Life Laboratory · SE
Area of research
Rheumatology · Pathology and Forensic Medicine
Research interest
Research focused on Rheumatoid arthritis and Lymphoma, with related work in Genome-wide association study, Missense mutation, Cancer. Notable publications include 'Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008—A Swedish population‐based study', 'Lymphoma development in patients with autoimmune and inflammatory disorders – What are the driving forces?', and 'Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial'.
h-index
citations
1,642
works
15
NIH funding
primary concept
email

Recent publications

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
Annals of the Rheumatic Diseases 2023cited by 87position: middledoi
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
Annals of the Rheumatic Diseases 2023cited by 51position: middledoi
Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells
Nature Communications 2022cited by 104position: middledoi
Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset
Annals of the Rheumatic Diseases 2022cited by 82position: middledoi
Strong Association of Combined Genetic Deficiencies in the Classical Complement Pathway With Risk of Systemic Lupus Erythematosus and Primary Sjögren's Syndrome
Arthritis & Rheumatology 2022cited by 34position: middledoi
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Annals of the Rheumatic Diseases 2021cited by 101position: middledoi
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice
Lara D. Veeken 2021cited by 81position: middledoi
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial
BMJ 2020cited by 112position: middledoi
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
Annals of the Rheumatic Diseases 2017cited by 93position: middledoi
Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?
Arthritis & Rheumatology 2016cited by 99position: middledoi
Reduced expression of <scp>TRIM</scp>21/Ro52 predicts poor prognosis in diffuse large B‐cell lymphoma patients with and without rheumatic disease
Journal of Internal Medicine 2015cited by 65position: middledoi
Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
Annals of the Rheumatic Diseases 2014cited by 104position: middledoi
Ankylosing Spondylitis, Psoriatic Arthritis, and Risk of Malignant Lymphoma: A Cohort Study Based on Nationwide Prospectively Recorded Data From Sweden
Arthritis & Rheumatology 2014cited by 73position: middledoi
Lymphoma development in patients with autoimmune and inflammatory disorders – What are the driving forces?
Seminars in Cancer Biology 2013cited by 185position: firstdoi
Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008—A Swedish population‐based study
International Journal of Cancer 2012cited by 371position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Johan Askling · Karolinska University Hospital8 papers (2013–2023)Nils Feltelius · Uppsala University5 papers (2014–2023)Karin E. Smedby · Karolinska University Hospital4 papers (2012–2016)Carin Backlin · Medical University of South Carolina3 papers (2014–2016)Karin Hellgren · Karolinska Institutet3 papers (2014–2017)Elisabet Lindqvist · Lund University3 papers (2021–2023) · 3 papers (2021–2023)Thomas Frisell · Karolinska Institutet3 papers (2021–2023)Christer Sundström · Science for Life Laboratory3 papers (2014–2016)Helena Forsblad‐d’Elia · Lund University3 papers (2021–2023)Hannah Bower · Karolinska Institutet3 papers (2021–2023)Katerina Chatzidionysiou · Karolinska University Hospital2 papers (2021–2021) · 2 papers (2021–2021)Daniela Di Giuseppe · Karolinska Institutet2 papers (2021–2023)Alf Kastbom · Rockefeller University2 papers (2021–2021)Christopher Sjöwall · Linköping University2 papers (2021–2021)Carl Turesson · Lund University2 papers (2021–2021)Lars Klareskog · Karolinska University Hospital2 papers (2021–2021)Bénédicte Delcoigne · Karolinska Institutet2 papers (2021–2023)H Wilczek · Karolinska Institutet1 papers (2012–2012)